Adverum Biotechnologies Inc (ADVM)
9.95
+0.16
(+1.63%)
USD |
NASDAQ |
May 02, 14:44
Adverum Biotechnologies Enterprise Value: 106.66M for May 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 01, 2024 | 106.66M |
| April 30, 2024 | 105.21M |
| April 29, 2024 | 101.27M |
| April 26, 2024 | 94.21M |
| April 25, 2024 | 98.36M |
| April 24, 2024 | 114.97M |
| April 23, 2024 | 131.78M |
| April 22, 2024 | 138.83M |
| April 19, 2024 | 138.83M |
| April 18, 2024 | 134.89M |
| April 17, 2024 | 139.04M |
| April 16, 2024 | 144.44M |
| April 15, 2024 | 142.78M |
| April 12, 2024 | 146.93M |
| April 11, 2024 | 151.91M |
| April 10, 2024 | 152.12M |
| April 09, 2024 | 152.74M |
| April 08, 2024 | 164.57M |
| April 05, 2024 | 165.40M |
| April 04, 2024 | 176.82M |
| April 03, 2024 | 180.55M |
| April 02, 2024 | 181.59M |
| April 01, 2024 | 191.76M |
| March 28, 2024 | 196.95M |
| March 27, 2024 | 207.74M |
| Date | Value |
|---|---|
| March 26, 2024 | 197.16M |
| March 25, 2024 | 213.76M |
| March 22, 2024 | 236.80M |
| March 21, 2024 | 209.61M |
| March 20, 2024 | 218.95M |
| March 19, 2024 | 245.93M |
| March 18, 2024 | 270.84M |
| March 15, 2024 | 256.31M |
| March 14, 2024 | 262.53M |
| March 13, 2024 | 277.06M |
| March 12, 2024 | 279.14M |
| March 11, 2024 | 274.99M |
| March 08, 2024 | 293.67M |
| March 07, 2024 | 301.65M |
| March 06, 2024 | 287.14M |
| March 05, 2024 | 293.36M |
| March 04, 2024 | 312.02M |
| March 01, 2024 | 312.02M |
| February 29, 2024 | 314.10M |
| February 28, 2024 | 311.59M |
| February 27, 2024 | 317.80M |
| February 26, 2024 | 307.44M |
| February 23, 2024 | 317.80M |
| February 22, 2024 | 338.52M |
| February 21, 2024 | 311.59M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-191.08M
Minimum
May 16 2022
1.762B
Maximum
Jun 23 2020
247.43M
Average
10.99M
Median
Jan 30 2024
Enterprise Value Benchmarks
| Karyopharm Therapeutics Inc | 103.75M |
| Ardelyx Inc | 1.401B |
| Minerva Neurosciences Inc | -24.13M |
| Arcutis Biotherapeutics Inc | 945.13M |
| 4D Molecular Therapeutics Inc | 973.64M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -23.71M |
| Total Expenses (Quarterly) | 26.16M |
| EPS Diluted (Quarterly) | -2.30 |
| Earnings Yield | -116.6% |
| Normalized Earnings Yield | -146.73 |